

## **LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**  
**{Cardboard box}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

DUOMYXIN, 3 400 IU/ml / 10 000 IU/ml, Eye drops, powder and solvent for solution

**2. STATEMENT OF ACTIVE SUBSTANCES**

Reconstituted solution

Neomycin (as sulfate) .....3,400 IU/mL

Polymyxin B (as sulfate) .....10,000 IU/mL

**3. PACKAGE SIZE**

Lyophilisate vial, 5 mL-solvent bottle, dropper

**4. TARGET SPECIES**

Dogs and cats.



**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Ocular use.



**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

EXP {mm/yyyy}

Once reconstituted use within 10 days.

<b>9. SPECIAL STORAGE PRECAUTIONS</b>
---------------------------------------

<b>10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”</b>
--

Read the package leaflet before use.

<b>11. THE WORDS “FOR ANIMAL TREATMENT ONLY”</b>
--

For animal treatment only.

<b>12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b>
--

Keep out of the sight and reach of children.

<b>13. NAME OF THE MARKETING AUTHORISATION HOLDER</b>
---

DOMES PHARMA

<b>14. MARKETING AUTHORISATION NUMBERS</b>
--

<b>15. BATCH NUMBER</b>
-------------------------

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

{Solvent - label}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

DUOMYXIN

Solvent



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

5 mL

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

EXP {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

{Lyophilisate / Reconstituted solution - label}

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

DUOMYXIN



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

3,400 IU/mL / 10,000 IU/mL

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

EXP {mm/yyyy}

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

DUOMYXIN, 3 400 IU/ml / 10 000 IU/ml, Eye drops, powder and solvent for solution for dogs and cats (AT, BE, DE, DK, ES, FI, IE, IT, LU, NO, PT, EL, PL, RO)

Duomycin, 3 400 IU/ml / 10 000 IU/ml, Eye drops, powder and solvent for solution for dogs and cats (SE)

### 2. Composition

#### Lyophilisate

One vial of 2 g contains:

#### **Active substances:**

Neomycin (as sulfate) .....17,000 IU

Polymyxin B (as sulfate) .....50,000 IU

White to cream powder.

#### Solvent

The 5-mL bottle contains:

#### **Excipient:**

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Benzalkonium chloride	0.50 mg

Practically limpid, colourless and practically particles-free solution.

#### Reconstituted solution

1 mL contains:

#### **Active substances:**

Neomycin (as sulfate) .....3,400 IU

Polymyxin B (as sulfate) .....10,000 IU

#### **Excipients:**

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Benzalkonium chloride	0.10 mg

Practically limpid, colourless to pale yellow, practically particles-free solution.

### 3. Target species

Dogs and cats.



#### **4. Indications for use**

Treatment of superficial eye infections caused by bacteria susceptible to polymyxin B and neomycin based on susceptibility testing.

#### **5. Contraindications**

Do not use in cases of known hypersensitivity to the active substances or to any of the excipients.

#### **6. Special warnings**

##### Special warnings:

None.

##### Special precautions for safe use in the target species:

Use of the veterinary medicinal product should be based on identification and susceptibility testing of the target pathogens. If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target bacteria at local/regional level.

Use of the veterinary medicinal product should be in accordance with official, national and regional antimicrobial policies.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to neomycin and may decrease the effectiveness of treatment with other aminoglycosides due to the potential for cross-resistance.

An antibiotic with a lower risk of antimicrobial resistance selection (lower AMEG category) should be used for first line treatment where susceptibility testing suggests the likely efficacy of this approach.

This antimicrobial combination should only be used where diagnostic testing has indicated the need for simultaneous administration of each of the active substances.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The veterinary medicinal product may cause hypersensitivity reactions following ingestion or skin contact due to the presence of neomycin, polymyxin B and benzalkonium chloride. People with known hypersensitivity to any of the components should avoid contact with the veterinary medicinal product. In case of accidental spillage onto skin rinse immediately with plenty of water. If you develop symptoms such as a skin rash following exposure, seek medical advice and show the package leaflet to the physician.

The veterinary medicinal product may cause irritation. Avoid contact with eyes. In case of accidental spillage into eyes, rinse immediately with plenty of water.

Wash hands after use.

##### Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment of the responsible veterinarian.

##### Interaction with other medicinal products and other forms of interaction:

None known.

##### Overdose:

None known.

##### Special restrictions for use and special conditions for use:

Not applicable.

Major incompatibilities:

None known.

## **7. Adverse events**

In dogs and cats:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):

Eye irritation and eye pain\*

\*These signs have been observed upon instillation of the eye drops.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that medicine has not worked, please contact, in the first instance your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder> using the contact details at the end of this leaflet, or via your national reporting system <{national system details}>.

## **8. Dosage for each species, routes and method of administration**

Ocular use.

The veterinary medicinal product is to be administered into the affected eye, at a dose of 2 drops, 3 to 4 times daily. Both eyes may be treated with the same dose at the same time, if necessary.

Duration of treatment: 8 to 10 days.



## **9. Advice on correct administration**

Clean hands carefully before handling and reconstituting the eyedrops solution in order to avoid microbiological contamination of the veterinary medicinal product. It is recommended that the reconstitution of the eyedrops is done by a veterinarian or a pharmacist.




Open the amber glass container by removing the aluminium cap and then the stopper.

Remove the screw cap of the solvent and add the solvent to the freeze dried powder in the amber glass container by gently squeezing the bottle. Make sure that all solvent is added.



Press the dropper (with cap) onto the vial.

The powder dissolves almost immediately, shaking gently helps to have an immediate homogeneous solution.



Remove the cap from the dropper to administer the veterinary medicinal product. Keep the dog's/cat's head steady in a slightly upright position. Hold the container in an upright position without touching the eye. Rest your hand/little finger on the forehead of the dog/cat to maintain distance between the container and the eye. Pull the eyelid of the affected eye downwards, this will form a little eyelid pouch. Gently squeeze the dropper to administer two drops into the eyelid pouch that you created. Be careful not to touch the dropper tip after opening the container and replace the cap after use.

#### **10. Withdrawal periods**

Not applicable.

#### **11. Special storage precautions**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: 10 days.

## **12. Special precautions for disposal**

Medicine should not be disposed of via wastewater <or household waste>. Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your <veterinary surgeon> <or> <pharmacist> how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. Marketing authorisation numbers and pack sizes**

XX/V/XXXXXXXX/XXXX

Box of 1 vial of lyophilisate, 1 bottle of 5 mL solvent and 1 dropper.

## **15. Date on which the package leaflet was last revised**

03/2023

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

## **16. Contact details**

Marketing authorisation holder <and contact details to report suspected adverse reactions>:

DOMES PHARMA  
3 Rue André Citroën  
63430 PONT-DU-CHATEAU  
France

Manufacturer responsible for batch release:

TUBILUX PHARMA  
VIA COSTARICA, 20/22  
00071 POMEZIA (RM)  
ITALY

Local representatives <and contact details to report suspected adverse reactions>:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

## **17. Other information**

